Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2015 2
2016 2
2017 9
2018 15
2019 25
2020 18
2021 32
2022 48
2023 26
2024 0

Text availability

Article attribute

Article type

Publication date

Similar articles for PMID: 35450960

135 results

Results by year

Filters applied: . Clear all
Page 1
Head-to-head comparisons of [68Ga]Ga-PSMA-11 PET/CT, multiparametric MRI, and prostate-specific antigen for the evaluation of therapeutic responses to neoadjuvant chemohormonal therapy in high-risk non-metastatic prostate cancer patients: a prospective study.
Ke ZB, Chen SM, Chen JY, Chen SH, You Q, Sun JB, Xue YT, Sun XL, Wu XH, Zheng QS, Wei Y, Xue XY, Xu N. Ke ZB, et al. Eur J Nucl Med Mol Imaging. 2023 Mar;50(4):1240-1251. doi: 10.1007/s00259-022-06047-6. Epub 2022 Nov 22. Eur J Nucl Med Mol Imaging. 2023. PMID: 36416906
Early molecular imaging response assessment based on determination of total viable tumor burden in [68Ga]Ga-PSMA-11 PET/CT independently predicts overall survival in [177Lu]Lu-PSMA-617 radioligand therapy.
Rosar F, Wenner F, Khreish F, Dewes S, Wagenpfeil G, Hoffmann MA, Schreckenberger M, Bartholomä M, Ezziddin S. Rosar F, et al. Eur J Nucl Med Mol Imaging. 2022 Apr;49(5):1584-1594. doi: 10.1007/s00259-021-05594-8. Epub 2021 Nov 2. Eur J Nucl Med Mol Imaging. 2022. PMID: 34725725 Free PMC article.
The Triple-Tracer strategy against Metastatic PrOstate cancer (3TMPO) study protocol.
Pouliot F, Beauregard JM, Saad F, Trudel D, Richard PO, Turcotte É, Rousseau É, Probst S, Kassouf W, Anidjar M, Camirand Lemyre F, Bouvet GF, Neveu B, Tétu A, Guérin B. Pouliot F, et al. BJU Int. 2022 Sep;130(3):314-322. doi: 10.1111/bju.15621. Epub 2021 Nov 11. BJU Int. 2022. PMID: 34674367 Free PMC article.
Therapeutic efficacy, prognostic variables and clinical outcome of 177Lu-PSMA-617 PRLT in progressive mCRPC following multiple lines of treatment: prognostic implications of high FDG uptake on dual tracer PET-CT vis-à-vis Gleason score in such cohort.
Suman S, Parghane RV, Joshi A, Prabhash K, Bakshi G, Talole S, Banerjee S, Basu S. Suman S, et al. Br J Radiol. 2019 Dec;92(1104):20190380. doi: 10.1259/bjr.20190380. Epub 2019 Nov 1. Br J Radiol. 2019. PMID: 31600089 Free PMC article.
Role of baseline 68Ga-PSMA PET/CT-derived whole-body volumetric parameters in predicting survival outcomes of metastatic castration-resistant prostate cancer patients receiving first-line treatment.
Telli TA, Ozguven S, Alan O, Filizoglu N, Ozturk MA, Sariyar N, Isik S, Arikan R, Demircan NC, Basoglu T, Cetin IA, Ones T, Ercelep O, Dane F, Yumuk PF. Telli TA, et al. Ann Nucl Med. 2022 Nov;36(11):964-975. doi: 10.1007/s12149-022-01785-x. Epub 2022 Aug 23. Ann Nucl Med. 2022. PMID: 35997890
135 results